On Assignment (ASGN -5.7%) shares are taking a bath after the company reported in-line revenue in Q3 but missed on EPS.
Gross margin dipped 70 bp Y/Y to 30.2% but was up 40 bp sequentially. "[C]ompression was primarily due to a higher mix of revenues from Apex, which carries a lower gross margin and a lower mix of permanent placement and conversion fees," noted CEO Peter Dameris.
Management expects Q4 revenue of $429M-$433M (consensus of $430.2M) and EPS of $0.31-$0.33 ($0.33).
Meanwhile, Wells Fargo downgraded ASGN to Perform while raising its PT range to $33-$34 (from $32-$33). Analyst Ed Caso cited valuation concerns, but believes "On Assignment is well positioned for above-market growth and gross margin due to its focus on the attractive IT (80% of revenue) and healthcare and life sciences (20% of revenue) markets." ASGN shares had climbed 76% in the last year through yesterday.